Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
180 public companies · 180 exchange-listed
180
Total Companies
180
Exchange Listed
158
Filed 10-K
25
States Represented
Total Sector Revenue
$94.11B
Aggregate of 101 companies with XBRL data
Avg Net Margin
-81.5%
Intensely competitive· Based on 101 filings
Sector Analysis · Sprytne.com
As of April 2026, the Biological Products, (No Diagnostic Substances) sector (SIC 2836) reports a combined revenue of $94.11B across 101 SEC-tracked entities. With an average net margin of -81.5%, this industry is classified as loss-making on average. AMGEN INC leads the sector with $36.75B in reported revenue. The data is derived exclusively from official SEC EDGAR XBRL submissions and reflects the most recently filed 10-K annual reports.
Data aggregated from SEC EDGAR XBRL submissions · Updated March 2026
| Rank | Company | Revenue | Net Income | Net Margin | vs Industry Avg |
|---|---|---|---|---|---|
| #1 | AMGEN INCAMGN | $36.75B | $7.71B | 21.0% | +102.5pp |
| #2 | GILEAD SCIENCES, INC.GILD | $29.44B | $8.51B | 28.9% | +110.4pp |
| #3 | BIOGEN INC.BIIB | $9.89B | $1.29B | 13.1% | +94.6pp |
| #4 | NEUROCRINE BIOSCIENCES INCNBIX | $2.86B | $478.6M | 16.7% | +98.2pp |
| #5 | EXELIXIS, INC.EXEL | $2.32B | $782.6M | 33.7% | +115.2pp |
| Industry Average | $931.8M | $87.5M | -81.5% | baseline | |
4D Molecular Therapeutics, Inc.
CIK: 0001650648 · DE · 10-K: 2026-03-18
Abpro Holdings, Inc.
CIK: 0001893219 · DE · 10-K: 2025-04-15
Acumen Pharmaceuticals, Inc.
CIK: 0001576885 · DE · 10-K: 2025-03-27
ADAPTIN BIO, INC.
CIK: 0001938571 · DE · 10-K: 2025-04-15
Adaptive Biotechnologies Corp
CIK: 0001478320 · WA · 10-K: 2026-02-26
ADMA BIOLOGICS, INC.
CIK: 0001368514 · DE · 10-K: 2026-02-25
Agentix Corp.
CIK: 0001603345 · NV · 10-K: 2025-07-16
AGENUS INC
CIK: 0001098972 · DE · 10-K: 2026-03-16
Agomab Therapeutics NV
CIK: 0002020932 · C9
AIM ImmunoTech Inc.
CIK: 0000946644 · DE · 10-K: 2025-03-27
Alector, Inc.
CIK: 0001653087 · · 10-K: 2026-02-25
Aligos Therapeutics, Inc.
CIK: 0001799448 · DE · 10-K: 2026-03-05
Allogene Therapeutics, Inc.
CIK: 0001737287 · · 10-K: 2026-03-12
Alpha Cognition Inc.
CIK: 0001655923 · A1 · 10-K: 2025-03-31
Alvotech
CIK: 0001898416 · N4
AMGEN INC
CIK: 0000318154 · DE · 10-K: 2026-02-13
ANAVEX LIFE SCIENCES CORP.
CIK: 0001314052 · · 10-K: 2025-11-25
Apogee Therapeutics, Inc.
CIK: 0001974640 · · 10-K: 2026-03-02
Aptose Biosciences Inc.
CIK: 0000882361 · A6 · 10-K: 2025-03-28
Arcellx, Inc.
CIK: 0001786205 · DE · 10-K: 2026-02-26
ARGENX SE
CIK: 0001697862 · P7
Armata Pharmaceuticals, Inc.
CIK: 0000921114 · WA · 10-K: 2025-03-21
Artiva Biotherapeutics, Inc.
CIK: 0001817241 · DE · 10-K: 2026-03-10
Atara Biotherapeutics, Inc.
CIK: 0001604464 · DE · 10-K: 2026-03-16
aTYR PHARMA INC
CIK: 0001339970 · DE · 10-K: 2026-03-05
Aura Biosciences, Inc.
CIK: 0001501796 · DE · 10-K: 2025-03-24
Autolus Therapeutics plc
CIK: 0001730463 · X0 · 10-K: 2025-03-20
Beam Therapeutics Inc.
CIK: 0001745999 · DE · 10-K: 2026-02-24
BIO-TECHNE Corp
CIK: 0000842023 · MN · 10-K: 2025-08-22
BioAtla, Inc.
CIK: 0001826892 · DE · 10-K: 2025-03-28
BioCardia, Inc.
CIK: 0000925741 · DE · 10-K: 2026-03-24
BIOCRYST PHARMACEUTICALS INC
CIK: 0000882796 · DE · 10-K: 2026-02-26
BIOGEN INC.
CIK: 0000875045 · DE · 10-K: 2026-02-06
BiomX Inc.
CIK: 0001739174 · DE · 10-K: 2026-02-19
BioNTech SE
CIK: 0001776985 · 2M
BIOSTEM TECHNOLOGIES
CIK: 0001658678 · FL
Black Diamond Therapeutics, Inc.
CIK: 0001701541 · · 10-K: 2026-03-16
Black Hawk Acquisition Corp
CIK: 0002000775 · · 10-K: 2026-03-06
BRAINSTORM CELL THERAPEUTICS INC.
CIK: 0001137883 · DE · 10-K: 2025-03-31
C4 Therapeutics, Inc.
CIK: 0001662579 · DE · 10-K: 2026-02-26
Cabaletta Bio, Inc.
CIK: 0001759138 · DE · 10-K: 2026-03-23
Calidi Biotherapeutics, Inc.
CIK: 0001855485 · DE · 10-K: 2025-03-31
Candel Therapeutics, Inc.
CIK: 0001841387 · DE · 10-K: 2026-03-12
Cardiff Oncology, Inc.
CIK: 0001213037 · DE · 10-K: 2026-02-24
Cardiol Therapeutics Inc.
CIK: 0001702123 · A6
Caribou Biosciences, Inc.
CIK: 0001619856 · DE · 10-K: 2026-03-05
CEL SCI CORP
CIK: 0000725363 · CO · 10-K: 2025-12-29
Cellectis S.A.
CIK: 0001627281 · I0
Century Therapeutics, Inc.
CIK: 0001850119 · DE · 10-K: 2026-03-12
CERO THERAPEUTICS HOLDINGS, INC.
CIK: 0001870404 · DE · 10-K: 2025-04-15
Showing 50 of 180 companies in this sector